Please login to the form below

Not currently logged in
Email:
Password:

Amarin

This page shows the latest Amarin news and features for those working in and with pharma, biotech and healthcare.

Amarin up as FDA speeds Vascepa’s cardiovascular claim review

Amarin up as FDA speeds Vascepa’s cardiovascular claim review

The news has also reignited speculation of a possible buyout of Amarin, with Pfizer rumoured to be among the companies interested in snapping it up. ... That speculation has helped Amarin’s stock rise more than 50% since the outcomes data was first

Latest news

  • Pfizer takeover rumour ignites Amarin shares Pfizer takeover rumour ignites Amarin shares

    Fish oil product shows great promise. Pfizer is rumoured to be on the brink of a deal to acquire small biopharma Amarin in the wake of stellar data for its purified ... The aim will be to build the pipeline and also add to revenue growth – and adding

  • The Midas Touch The Midas Touch

    Then along comes Amarin. By investing in the isolation of a single compound from the soup that is fish-oil, they have developed a product called Vascepa. ... Well done Amarin. The practical lesson of Amarin’s Vascepa for the rest of us is hidden in

  • Amarin hits jackpot with astonishing heart benefits from fish oil product Amarin hits jackpot with astonishing heart benefits from fish oil product

    Amarin CEO John Thero. “We are delighted with these topline study results,” said John Thero, president and CEO of Amarin. ... of LDL-C control with standard of care statin therapy in studied patients,” added Craig Granowitz, MD, PhD, senior vice

  • Amarin sues FDA over off-label policy Amarin sues FDA over off-label policy

    Claims block on discussing off-label uses conflicts freedom of speech. Irish pharma company Amarin Corp is suing the FDA, claiming that a block on discussing off-label uses for drugs ... Amarin is in the process of carrying out a cardiovascular outcomes

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the

More from news
Approximately 5 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Teva's Mark Salyer joins Amarin Teva's Mark Salyer joins Amarin

    Takes up newly-created chief commercial officer role. Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer. ... Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

World Mental Health Day 2019: Employment and Mental Illness
Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2019....
Changing direction
Changing direction: adapting to a rapidly-evolving environment
Chris Ross examines why creative partnerships could be key to commercial success in today’s healthcare marketplace...
customer journey
Understanding the patient journey
What we can learn from customer service...

Infographics